首页 > 最新文献

Kidney and dialysis最新文献

英文 中文
Opinion on the (Hemo)dialysate Sodium Prescription: Dialysate Sodium Prescription Should Not Be Considered in Isolation 对(血液)透析液钠处方的意见:透析液钠处方不应单独考虑
Pub Date : 2021-12-02 DOI: 10.3390/kidneydial1020021
K. Ng, I. Dasgupta
With advances in hemodialysis technology and the desire to achieve cardiovascular stability during dialysis, prescribed dialysate sodium concentration has gradually increased over the years. Short-term trials suggest low dialysate sodium (<138 mEq/L) is beneficial in reducing interdialytic weight gain, pre- and post-dialysis BP, and predialysis serum sodium; but it increases intradialytic hypotensive episodes. We believe dialysate sodium prescription cannot be considered in isolation. Our approach is to use patient symptoms, meticulous fluid volume management and low temperature dialysate in conjunction with neutral dialysate sodium in managing our dialysis patients. Long-term trials are needed to inform optimum dialysate sodium prescription.
随着血液透析技术的进步以及在透析过程中实现心血管稳定的愿望,处方透析液钠浓度多年来逐渐增加。短期试验表明,低透析液钠(<138 mEq/L)有利于减少透析间期体重增加、透析前和透析后血压和透析前血清钠;但它增加了分析性低血压发作。我们认为不能孤立地考虑透析钠处方。我们的方法是使用患者症状,细致的液体容量管理和低温透析结合中性透析钠来管理我们的透析患者。需要长期试验来为最佳透析液钠处方提供信息。
{"title":"Opinion on the (Hemo)dialysate Sodium Prescription: Dialysate Sodium Prescription Should Not Be Considered in Isolation","authors":"K. Ng, I. Dasgupta","doi":"10.3390/kidneydial1020021","DOIUrl":"https://doi.org/10.3390/kidneydial1020021","url":null,"abstract":"With advances in hemodialysis technology and the desire to achieve cardiovascular stability during dialysis, prescribed dialysate sodium concentration has gradually increased over the years. Short-term trials suggest low dialysate sodium (<138 mEq/L) is beneficial in reducing interdialytic weight gain, pre- and post-dialysis BP, and predialysis serum sodium; but it increases intradialytic hypotensive episodes. We believe dialysate sodium prescription cannot be considered in isolation. Our approach is to use patient symptoms, meticulous fluid volume management and low temperature dialysate in conjunction with neutral dialysate sodium in managing our dialysis patients. Long-term trials are needed to inform optimum dialysate sodium prescription.","PeriodicalId":74038,"journal":{"name":"Kidney and dialysis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44589961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sodium in Hemodialysis Fluid 血液透析液中的钠
Pub Date : 2021-12-02 DOI: 10.3390/kidneydial1020020
S. Agarwal
The principal aim of dialysis in relation to sodium is that dialysate sodium should not be low enough to cause intradialytic hypotension and cramps, and should not be high enough to cause interdialytic weight gain and hypertension. Dialysis sodium at 138 meq/L is supposed to be neutral and for most patients, this remains the standard sodium level for regular long-term dialysis. In my opinion, sodium should be changed temporarily from this level to 142 meq/L in selected patients only for a few dialysis sessions, where the cause of intradialytic hypotension is not obvious. In patients who regularly go into intradialytic hypotension and whose cause of intradialytic hypotension is unclear or cannot be corrected, sodium profiling should be used for maintenance dialysis. There is no consensus on the level of sodium, although I think 142 meq/L for the initial hour followed by a decrease to 138 meq/L in the last hour is sensible.
与钠有关的透析的主要目的是透析液钠不应低到足以引起透析内低血压和痉挛,也不应高到足以引起分析间体重增加和高血压。138meq/L的透析钠应该是中性的,对大多数患者来说,这仍然是常规长期透析的标准钠水平。在我看来,在选定的患者中,钠应该暂时从这个水平改变到142meq/L,只在几次透析中进行,因为透析中低血压的原因并不明显。对于经常出现透析内低血压且透析内低血压原因不明或无法纠正的患者,应使用钠谱进行维持性透析。关于钠的水平还没有达成共识,尽管我认为在最初的一小时内达到142毫克当量/升,然后在最后一小时降至138毫克当量/L是合理的。
{"title":"Sodium in Hemodialysis Fluid","authors":"S. Agarwal","doi":"10.3390/kidneydial1020020","DOIUrl":"https://doi.org/10.3390/kidneydial1020020","url":null,"abstract":"The principal aim of dialysis in relation to sodium is that dialysate sodium should not be low enough to cause intradialytic hypotension and cramps, and should not be high enough to cause interdialytic weight gain and hypertension. Dialysis sodium at 138 meq/L is supposed to be neutral and for most patients, this remains the standard sodium level for regular long-term dialysis. In my opinion, sodium should be changed temporarily from this level to 142 meq/L in selected patients only for a few dialysis sessions, where the cause of intradialytic hypotension is not obvious. In patients who regularly go into intradialytic hypotension and whose cause of intradialytic hypotension is unclear or cannot be corrected, sodium profiling should be used for maintenance dialysis. There is no consensus on the level of sodium, although I think 142 meq/L for the initial hour followed by a decrease to 138 meq/L in the last hour is sensible.","PeriodicalId":74038,"journal":{"name":"Kidney and dialysis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49459419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evidence from Studies of Patient-Reported Outcomes Supports a Policy of Using a Dialysate Sodium Concentration of 140 mEq/L for the Majority of Patients 来自患者报告结果研究的证据支持大多数患者使用透析液钠浓度为140 mEq/L的政策
Pub Date : 2021-12-01 DOI: 10.3390/kidneydial1020018
H. Rayner
The best evidence available to guide a policy for prescribing the dialysate sodium concentration, [DNa], comes from large randomly selected observational studies, such as the Dialysis Outcomes and Practice Patterns Study (DOPPS). These show that, after adjustment for differences in demographics and comorbidity, using a [DNa] lower than 140 mEq/L is associated with patients taking longer to recover after a dialysis treatment, worse symptoms of kidney failure, a higher score for the burden of kidney disease and worse mental and physical health-related quality of life. It is also associated with greater risks of being admitted to hospital and dying. These outcomes are more important than any medically determined surrogate outcome, such as the control of blood pressure or interdialytic weight gain. The most appropriate policy for prescribing the dialysate sodium concentration is to use a [DNa] of 140 mEq/L for the majority of patients.
指导透析液钠浓度(DNa)处方政策的最佳证据来自于大型随机选择的观察性研究,如透析结果和实践模式研究(DOPPS)。这些研究表明,在调整了人口统计学和合并症的差异后,使用低于140 mEq/L的[DNa]与患者透析治疗后恢复时间更长、肾衰竭症状更严重、肾脏疾病负担评分更高、精神和身体健康相关生活质量更差相关。它还与入院和死亡的更大风险有关。这些结果比任何医学上确定的替代结果更重要,如血压控制或透析期间体重增加。对于大多数患者,最合适的透析液钠浓度处方是使用140 mEq/L [DNa]。
{"title":"Evidence from Studies of Patient-Reported Outcomes Supports a Policy of Using a Dialysate Sodium Concentration of 140 mEq/L for the Majority of Patients","authors":"H. Rayner","doi":"10.3390/kidneydial1020018","DOIUrl":"https://doi.org/10.3390/kidneydial1020018","url":null,"abstract":"The best evidence available to guide a policy for prescribing the dialysate sodium concentration, [DNa], comes from large randomly selected observational studies, such as the Dialysis Outcomes and Practice Patterns Study (DOPPS). These show that, after adjustment for differences in demographics and comorbidity, using a [DNa] lower than 140 mEq/L is associated with patients taking longer to recover after a dialysis treatment, worse symptoms of kidney failure, a higher score for the burden of kidney disease and worse mental and physical health-related quality of life. It is also associated with greater risks of being admitted to hospital and dying. These outcomes are more important than any medically determined surrogate outcome, such as the control of blood pressure or interdialytic weight gain. The most appropriate policy for prescribing the dialysate sodium concentration is to use a [DNa] of 140 mEq/L for the majority of patients.","PeriodicalId":74038,"journal":{"name":"Kidney and dialysis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47140601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Personal and Practical Answer from a Clinical Perspective 从临床角度的个人和实用的答案
Pub Date : 2021-12-01 DOI: 10.3390/kidneydial1020019
B. Canaud
Restoring sodium and fluid homeostasis in hemodialysis (HD) patients is a crucial aim to reduce cardiovascular burden and improve global outcome. This crucial target is achieved at maximum in one quarter of HD patients according to a recent study. Sodium and fluid balance relies on a multitarget approach involving dietary salt restriction, dialysis salt mass removal and eventually residual kidney function. Salt mass removal in hemodialysis relies on ultrafiltration (convective sodium), the dialysate–plasma sodium gradient (diffusive sodium) and total treatment time. Manual dialysate sodium prescription has three major aims: dialysate–plasma sodium gradient; sodium mass removal target; hemodialysis tolerance and patient risks. In the future, automated dialysate sodium adjustment by HD machine will facilitate this aim.
恢复血液透析(HD)患者的钠和液体稳态是减少心血管负担和改善全球结果的关键目标。根据最近的一项研究,这一关键目标最多可在四分之一的HD患者中实现。钠和液体平衡依赖于一种多目标方法,包括饮食盐限制、透析盐去除和最终残余肾功能。血液透析中的盐分去除依赖于超滤(对流钠)、透析液-血浆钠梯度(扩散钠)和总治疗时间。手动透析液钠处方有三个主要目的:透析液-血浆钠梯度;钠质量去除靶;血液透析耐受性和患者风险。未来,HD机自动调节透析液钠将有助于实现这一目标。
{"title":"A Personal and Practical Answer from a Clinical Perspective","authors":"B. Canaud","doi":"10.3390/kidneydial1020019","DOIUrl":"https://doi.org/10.3390/kidneydial1020019","url":null,"abstract":"Restoring sodium and fluid homeostasis in hemodialysis (HD) patients is a crucial aim to reduce cardiovascular burden and improve global outcome. This crucial target is achieved at maximum in one quarter of HD patients according to a recent study. Sodium and fluid balance relies on a multitarget approach involving dietary salt restriction, dialysis salt mass removal and eventually residual kidney function. Salt mass removal in hemodialysis relies on ultrafiltration (convective sodium), the dialysate–plasma sodium gradient (diffusive sodium) and total treatment time. Manual dialysate sodium prescription has three major aims: dialysate–plasma sodium gradient; sodium mass removal target; hemodialysis tolerance and patient risks. In the future, automated dialysate sodium adjustment by HD machine will facilitate this aim.","PeriodicalId":74038,"journal":{"name":"Kidney and dialysis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42245455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Dialysate Sodium—One Size Unlikely to Fit All 透析液钠——一种规格不可能适合所有人
Pub Date : 2021-11-30 DOI: 10.3390/kidneydial1020016
Finnian R. Mc Causland
The role of medical director of a hemodialysis unit has become increasingly complex. Among the many roles it encompasses, the delivery of safe and effective dialysis treatments requires constant review, synthesis, and interpretation of the medical literature. Despite decades of experience with hemodialysis, the evidence base for dialysate prescription is relatively limited, with the choice of dialysate sodium being a prime example. The ask of this exercise was to imagine ourselves as the medical director of a new hemodialysis unit and to consider factors influencing the choice of dialysate sodium. While fiscal considerations are indeed important, one hopes that these align with the delivery of clinical care to improve patient well-being. Therefore, my approach was to focus on exploring the clinical responsibilities of a medical director in the choice of dialysate sodium. As such, after reviewing the evidence to date, my ‘default’ dialysate sodium prescription would be 140 mmol/L, but I would retain the option of individualizing treatment for certain patients until further evidence becomes available.
血液透析单位的医务主任的角色变得越来越复杂。在它包含的许多角色中,提供安全有效的透析治疗需要不断审查,综合和解释医学文献。尽管有几十年的血液透析经验,透析液处方的证据基础相对有限,透析液钠的选择是一个主要的例子。这个练习的要求是想象我们自己是一个新的血液透析单位的医疗主任,并考虑影响透析液钠选择的因素。虽然财政方面的考虑确实很重要,但人们希望这些考虑与临床护理的提供相一致,以改善患者的福祉。因此,我的方法是专注于探索医学主任在透析液钠选择方面的临床责任。因此,在回顾了迄今为止的证据后,我的“默认”透析液钠处方将是140 mmol/L,但我会保留对某些患者进行个体化治疗的选择,直到获得进一步的证据。
{"title":"Dialysate Sodium—One Size Unlikely to Fit All","authors":"Finnian R. Mc Causland","doi":"10.3390/kidneydial1020016","DOIUrl":"https://doi.org/10.3390/kidneydial1020016","url":null,"abstract":"The role of medical director of a hemodialysis unit has become increasingly complex. Among the many roles it encompasses, the delivery of safe and effective dialysis treatments requires constant review, synthesis, and interpretation of the medical literature. Despite decades of experience with hemodialysis, the evidence base for dialysate prescription is relatively limited, with the choice of dialysate sodium being a prime example. The ask of this exercise was to imagine ourselves as the medical director of a new hemodialysis unit and to consider factors influencing the choice of dialysate sodium. While fiscal considerations are indeed important, one hopes that these align with the delivery of clinical care to improve patient well-being. Therefore, my approach was to focus on exploring the clinical responsibilities of a medical director in the choice of dialysate sodium. As such, after reviewing the evidence to date, my ‘default’ dialysate sodium prescription would be 140 mmol/L, but I would retain the option of individualizing treatment for certain patients until further evidence becomes available.","PeriodicalId":74038,"journal":{"name":"Kidney and dialysis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47040673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vascular Access Flow during Dialysis: Does Needle Orientation Matter? 透析期间血管通路流动:针的方向有影响吗?
Pub Date : 2021-11-30 DOI: 10.3390/kidneydial1020017
G. Tsangalis, Valérie Loizon
Background: Monitoring of vascular access outflow (VAO) in dialysis is based on the indicator dilution method by ultrasound (UD). The role of arterial needle orientation in VAO measurement is not clear. We compared the impact of the retrograde (RET) versus the antegrade orientation (ANT) in terms of (a) VAO (UD) and (b) dialysis adequacy. Moreover, we compared VAO (UD ANT and RET orientation) with VAO measured by Doppler ultrasound. Methods: 22 patients participated in the study. Inclusion criteria: Dialysis > 6 months with a functioning AVF, no stenosis, no active infection, EF > 45% and informed consent. 4 flow measurements were taken on the same dialysis day (4 consecutive weeks). To account for blood pressure variation, we “corrected” VAO for a mean arterial pressure of 100 mmHg. Doppler VAO was measured just before dialysis. Means were compared by the paired t-test. For correlation and agreement, linear regression and Bland-Altman analysis were performed respectively. Results: Mean VAO (UD) was higher in the (ANT) versus the (RET) orientation: 1286.17 mL/min (SD = 455.78, 95%CI = 1084–1488) versus 1189.96 mL/min (SD = 401.05, 95%CI = 1012–1368) (p = 0.013) with a mean difference of 96.21 mL/min (5.66%). Mean Kt/V (RET orientation) was 1.57 (SD = 0.10, 95%CI = 1.52–1.61) versus 1,55 (SD = 0.10, 95%CI = 1.50–1.60) (ANT) orientation (p = 0.062). Recirculation was always 0%. The mean VAO (Doppler) was 1079.54 mL/min (SD = 356.04, 95%CI = 922–1237), 16% lower than VAO measured by UD with (ANT) orientation (p = 0.009) and 9.3% lower than the VAO in the (RET) orientation (p = 0.113). Linear regression analysis showed that VA flows (ANT versus RET) orientation of the needle correlates well between them (r = 0.93, p < 0.001) but show poor agreement (Bland–Altman analysis). Conclusion: VAO (UD) in the RET orientation was significantly lower than VAO in the ANT orientation and more consistent with VAO assessed by Doppler without influencing dialysis adequacy. Therefore, when using UD for VAO surveillance, the RET orientation should be used.
背景:透析中血管通路流出(VAO)的监测是基于超声指示剂稀释法(UD)。动脉针方向在VAO测量中的作用尚不清楚。我们比较了逆行(RET)与顺行定向(ANT)在(a)VAO(UD)和(b)透析充分性方面的影响。此外,我们将VAO(UD-ANT和RET方位)与多普勒超声测量的VAO进行了比较。方法:22例患者参与本研究。纳入标准:透析>6个月,AVF功能正常,无狭窄,无活动性感染,EF>45%,知情同意。在同一透析日(连续4周)进行4次流量测量。为了解释血压变化,我们将VAO“校正”为平均动脉压100毫米汞柱。在透析前测量多普勒VAO。平均值通过配对t检验进行比较。对于相关性和一致性,分别进行了线性回归和Bland-Altman分析。结果:(ANT)方向与(RET)方向的平均VAO(UD)更高:1286.17 mL/min(SD=455.78,95%CI=1084–1488)与1189.96 mL/min(SD=401.05,95%CI=1012–1368)(p=0.013),平均差异为96.21 mL/min(5.66%)。平均Kt/V(RET方向)为1.57(SD=0.10,95%CI=1.52–1.61)与1.55(SD=.10,95%CI=1.50–1.60)(ANT方向)(p=0.062)。再循环始终为0%。平均VAO(多普勒)为1079.54 mL/min(SD=356.04,95%CI=922–1237),在(ANT)方向上比UD测量的VAO低16%(p=0.009),在(RET)方向下比VAO低9.3%(p=0.113)。线性回归分析表明,VA流量(ANT与RET)针的方向之间相关性良好(r=0.93,p<0.001),但一致性较差(Bland–Altman分析)。结论:RET方向的VAO(UD)显著低于ANT方向的VAO,并且与多普勒评估的VAO更一致,而不影响透析的充分性。因此,当使用UD进行VAO监测时,应使用RET方向。
{"title":"Vascular Access Flow during Dialysis: Does Needle Orientation Matter?","authors":"G. Tsangalis, Valérie Loizon","doi":"10.3390/kidneydial1020017","DOIUrl":"https://doi.org/10.3390/kidneydial1020017","url":null,"abstract":"Background: Monitoring of vascular access outflow (VAO) in dialysis is based on the indicator dilution method by ultrasound (UD). The role of arterial needle orientation in VAO measurement is not clear. We compared the impact of the retrograde (RET) versus the antegrade orientation (ANT) in terms of (a) VAO (UD) and (b) dialysis adequacy. Moreover, we compared VAO (UD ANT and RET orientation) with VAO measured by Doppler ultrasound. Methods: 22 patients participated in the study. Inclusion criteria: Dialysis > 6 months with a functioning AVF, no stenosis, no active infection, EF > 45% and informed consent. 4 flow measurements were taken on the same dialysis day (4 consecutive weeks). To account for blood pressure variation, we “corrected” VAO for a mean arterial pressure of 100 mmHg. Doppler VAO was measured just before dialysis. Means were compared by the paired t-test. For correlation and agreement, linear regression and Bland-Altman analysis were performed respectively. Results: Mean VAO (UD) was higher in the (ANT) versus the (RET) orientation: 1286.17 mL/min (SD = 455.78, 95%CI = 1084–1488) versus 1189.96 mL/min (SD = 401.05, 95%CI = 1012–1368) (p = 0.013) with a mean difference of 96.21 mL/min (5.66%). Mean Kt/V (RET orientation) was 1.57 (SD = 0.10, 95%CI = 1.52–1.61) versus 1,55 (SD = 0.10, 95%CI = 1.50–1.60) (ANT) orientation (p = 0.062). Recirculation was always 0%. The mean VAO (Doppler) was 1079.54 mL/min (SD = 356.04, 95%CI = 922–1237), 16% lower than VAO measured by UD with (ANT) orientation (p = 0.009) and 9.3% lower than the VAO in the (RET) orientation (p = 0.113). Linear regression analysis showed that VA flows (ANT versus RET) orientation of the needle correlates well between them (r = 0.93, p < 0.001) but show poor agreement (Bland–Altman analysis). Conclusion: VAO (UD) in the RET orientation was significantly lower than VAO in the ANT orientation and more consistent with VAO assessed by Doppler without influencing dialysis adequacy. Therefore, when using UD for VAO surveillance, the RET orientation should be used.","PeriodicalId":74038,"journal":{"name":"Kidney and dialysis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46364685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Combining Diffusion, Convection and Absorption: A Pilot Study of Polymethylmethacrylate versus Polysulfone Membranes in the Removal of P-Cresyl Sulfate by Postdilution On-Line Hemodiafiltration 结合扩散、对流和吸收:聚甲基丙烯酸甲酯膜与聚砜膜在线稀释血液透析滤除对甲酰硫酸盐的中试研究
Pub Date : 2021-11-09 DOI: 10.3390/kidneydial1020015
P. Molina, J. Peiró, M. Martínez-Gómez, Belén Vizcaíno, C. Esteller, Mercedes González-Moya, María García-Valdelvira, Mariola D. Molina, F. Maduell
Dialytic clearance of p-cresyl sulfate (pCS) and other protein-bound toxins is limited by diffusive and convective therapies, and only a few studies have examined how to improve their removal by adsorptive membranes. This study tested the hypothesis that high-flux polymethylmethacrylate (PMMA) dialysis membranes with adsorptive capacity increase pCS removal compared to polysulfone membranes, in a postdilution on-line hemodiafiltration (OL-HDF) session. Thirty-five stable hemodialysis patients randomly completed a single study of 4 h OL-HDF with PMMA (BG2.1U, Toray®, Tokyo, Japan) and polysulfone (TS2.1, Toray®) membranes. The primary endpoint was serum pCS reduction ratios (RRs) obtained with each dialyzer. Secondary outcomes included RRs of other solutes such as β2-microglobulin, the convective volume obtained after each dialysis session, and the dialysis dose estimated by ionic dialysance (Kt) and urea kinetics (Kt/V). The RRs for pCS were higher with the PMMA membrane than those obtained with polysulfone membrane (88.9% vs. 58.9%; p < 0.001), whereas the β2-microglobulin RRs (67.5% vs. 81.0%; p < 0.001), Kt (60.2 ± 8.7 vs. 65.5 ± 9.4 L; p = 0.01), Kt/V (1.9 ± 0.4 vs. 2.0 ± 0.5; p = 0.03), and the convection volume (18.8 ± 2.8 vs. 30.3 ± 7.8 L/session; p < 0.001) were significantly higher with polysulfone membrane. In conclusion, pCS removal by OL-HDF was superior with high-flux PMMA membranes, appearing to be a good dialysis strategy for improving dialytic clearance of pCS, enabling an acceptable clearance of β2-microglobulin and small solutes.
对甲酚硫酸酯(pCS)和其他蛋白质结合毒素的透析清除受到扩散和对流疗法的限制,只有少数研究研究探讨了如何通过吸附膜提高其清除率。本研究在稀释后在线血液透析过滤(OL-HDF)过程中检验了具有吸附能力的高通量聚甲基丙烯酸甲酯(PMMA)透析膜与聚砜膜相比增加pCS去除的假设。35名稳定的血液透析患者随机完成了一项使用PMMA(BG2.1U,Toray®,日本东京)和聚砜(TS2.1,Toray™)膜的4小时OL-HDF的单一研究。主要终点是用每个透析器获得的血清pCS减少率(RR)。次要结果包括其他溶质的RR,如β2-微球蛋白,每次透析后获得的对流体积,以及通过离子透析(Kt)和尿素动力学(Kt/V)估计的透析剂量。PMMA膜对pCS的RR高于聚砜膜(88.9%对58.9%;p<0.001),而β2-微球蛋白RR(67.5%对81.0%;p<001)、Kt(60.2±8.7对65.5±9.4L;p=0.01)、Kt/V(1.9±0.4对2.0±0.5;p=0.03)、,聚砜膜的对流量(18.8±2.8 vs.30.3±7.8 L/次;p<0.001)显著高于聚砜膜。总之,OL-HDF对pCS的去除优于高通量PMMA膜,这似乎是一种很好的透析策略,可以提高pCS的透析清除率,使β2-微球蛋白和小溶质的清除率达到可接受的水平。
{"title":"Combining Diffusion, Convection and Absorption: A Pilot Study of Polymethylmethacrylate versus Polysulfone Membranes in the Removal of P-Cresyl Sulfate by Postdilution On-Line Hemodiafiltration","authors":"P. Molina, J. Peiró, M. Martínez-Gómez, Belén Vizcaíno, C. Esteller, Mercedes González-Moya, María García-Valdelvira, Mariola D. Molina, F. Maduell","doi":"10.3390/kidneydial1020015","DOIUrl":"https://doi.org/10.3390/kidneydial1020015","url":null,"abstract":"Dialytic clearance of p-cresyl sulfate (pCS) and other protein-bound toxins is limited by diffusive and convective therapies, and only a few studies have examined how to improve their removal by adsorptive membranes. This study tested the hypothesis that high-flux polymethylmethacrylate (PMMA) dialysis membranes with adsorptive capacity increase pCS removal compared to polysulfone membranes, in a postdilution on-line hemodiafiltration (OL-HDF) session. Thirty-five stable hemodialysis patients randomly completed a single study of 4 h OL-HDF with PMMA (BG2.1U, Toray®, Tokyo, Japan) and polysulfone (TS2.1, Toray®) membranes. The primary endpoint was serum pCS reduction ratios (RRs) obtained with each dialyzer. Secondary outcomes included RRs of other solutes such as β2-microglobulin, the convective volume obtained after each dialysis session, and the dialysis dose estimated by ionic dialysance (Kt) and urea kinetics (Kt/V). The RRs for pCS were higher with the PMMA membrane than those obtained with polysulfone membrane (88.9% vs. 58.9%; p < 0.001), whereas the β2-microglobulin RRs (67.5% vs. 81.0%; p < 0.001), Kt (60.2 ± 8.7 vs. 65.5 ± 9.4 L; p = 0.01), Kt/V (1.9 ± 0.4 vs. 2.0 ± 0.5; p = 0.03), and the convection volume (18.8 ± 2.8 vs. 30.3 ± 7.8 L/session; p < 0.001) were significantly higher with polysulfone membrane. In conclusion, pCS removal by OL-HDF was superior with high-flux PMMA membranes, appearing to be a good dialysis strategy for improving dialytic clearance of pCS, enabling an acceptable clearance of β2-microglobulin and small solutes.","PeriodicalId":74038,"journal":{"name":"Kidney and dialysis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41612183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Do Exercise, Physical Activity, Dietetic, or Combined Interventions Improve Body Weight in New Kidney Transplant Recipients? A Narrative Systematic Review and Meta-Analysis 运动、体育活动、饮食或联合干预能改善新肾移植受者的体重吗?叙事系统综述与元分析
Pub Date : 2021-10-02 DOI: 10.3390/kidneydial1020014
E. Castle, E. McBride, J. Greenwood, K. Bramham, J. Chilcot, S. Greenwood
Weight gain within the first year of kidney transplantation is associated with adverse outcomes. This narrative systematic review and meta-analysis examines the effect of exercise, physical activity, dietary, and/or combined interventions on body weight and body mass index (BMI) within the first year of kidney transplantation. Seven databases were searched from January 1985 to April 2021 (Prospero ID: CRD42019140865), using a ‘Population, Intervention, Controls, Outcome’ (PICO) framework. The risk-of-bias was assessed by two reviewers. A random-effects meta-analysis was conducted on randomized controlled trials (RCTs) that included post-intervention body weight or BMI values. Of the 1197 articles screened, sixteen met the search criteria. Ten were RCTs, and six were quasi-experimental studies, including a total of 1821 new kidney transplant recipients. The sample sizes ranged from 8 to 452. Interventions (duration and type) were variable. Random-effects meta-analysis revealed no significant difference in post-intervention body weight (−2.5 kg, 95% CI −5.22 to 0.22) or BMI (−0.4 kg/m2, 95% CI −1.33 to 0.54). Despite methodological variance, statistical heterogeneity was not significant. Sensitivity analysis suggests combined interventions warrant further investigation. Five RCTs were classified as ‘high-risk’, one as ‘some-concerns’, and four as ‘low-risk’ for bias. We did not find evidence that dietary, exercise, or combined interventions led to significant changes in body weight or BMI post kidney transplantation. The number and quality of intervention studies are low. Higher quality RCTs are needed to evaluate the immediate and longer-term effects of combined interventions on body weight in new kidney transplant recipients.
肾移植第一年内的体重增加与不良后果有关。这篇叙述性系统综述和荟萃分析研究了肾移植第一年内运动、体育活动、饮食和/或联合干预对体重和体重指数(BMI)的影响。从1985年1月到2021年4月,使用“人口、干预、控制、结果”(PICO)框架搜索了七个数据库(Prospero ID:CRD42019140865)。两名评审员对偏倚风险进行了评估。对随机对照试验(RCT)进行随机效应荟萃分析,包括干预后的体重或BMI值。在筛选的1197篇文章中,有16篇符合搜索标准。10项为随机对照试验,6项为准实验研究,包括1821名新的肾移植受者。样本量从8到452个不等。干预措施(持续时间和类型)各不相同。随机效应荟萃分析显示,干预后体重(-2.5 kg,95%CI−5.22至0.22)或BMI(-0.4 kg/m2,95%CI–1.33至0.54)没有显著差异。尽管存在方法学差异,但统计异质性并不显著。敏感性分析表明,联合干预措施值得进一步调查。五项随机对照试验被归类为“高风险”,一项为“一些担忧”,四项为“低风险”偏倚。我们没有发现饮食、运动或联合干预导致肾移植后体重或BMI显著变化的证据。干预研究的数量和质量都很低。需要更高质量的随机对照试验来评估联合干预对新肾移植受者体重的即时和长期影响。
{"title":"Do Exercise, Physical Activity, Dietetic, or Combined Interventions Improve Body Weight in New Kidney Transplant Recipients? A Narrative Systematic Review and Meta-Analysis","authors":"E. Castle, E. McBride, J. Greenwood, K. Bramham, J. Chilcot, S. Greenwood","doi":"10.3390/kidneydial1020014","DOIUrl":"https://doi.org/10.3390/kidneydial1020014","url":null,"abstract":"Weight gain within the first year of kidney transplantation is associated with adverse outcomes. This narrative systematic review and meta-analysis examines the effect of exercise, physical activity, dietary, and/or combined interventions on body weight and body mass index (BMI) within the first year of kidney transplantation. Seven databases were searched from January 1985 to April 2021 (Prospero ID: CRD42019140865), using a ‘Population, Intervention, Controls, Outcome’ (PICO) framework. The risk-of-bias was assessed by two reviewers. A random-effects meta-analysis was conducted on randomized controlled trials (RCTs) that included post-intervention body weight or BMI values. Of the 1197 articles screened, sixteen met the search criteria. Ten were RCTs, and six were quasi-experimental studies, including a total of 1821 new kidney transplant recipients. The sample sizes ranged from 8 to 452. Interventions (duration and type) were variable. Random-effects meta-analysis revealed no significant difference in post-intervention body weight (−2.5 kg, 95% CI −5.22 to 0.22) or BMI (−0.4 kg/m2, 95% CI −1.33 to 0.54). Despite methodological variance, statistical heterogeneity was not significant. Sensitivity analysis suggests combined interventions warrant further investigation. Five RCTs were classified as ‘high-risk’, one as ‘some-concerns’, and four as ‘low-risk’ for bias. We did not find evidence that dietary, exercise, or combined interventions led to significant changes in body weight or BMI post kidney transplantation. The number and quality of intervention studies are low. Higher quality RCTs are needed to evaluate the immediate and longer-term effects of combined interventions on body weight in new kidney transplant recipients.","PeriodicalId":74038,"journal":{"name":"Kidney and dialysis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43634866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Vascular Access, Complications and Survival in Incident Hemodialysis Patients 血液透析患者的血管通路、并发症和生存率
Pub Date : 2021-09-30 DOI: 10.3390/kidneydial1020013
M. Torreggiani, L. Bernasconi, M. Colucci, Simone Accarino, E. Pasquinucci, V. Esposito, G. Sileno, C. Esposito
The arteriovenous fistula (AVF) has long been considered the optimal vascular access. However, the evolving characteristics of the ageing dialysis population limit the creation of an AVF in all patients. Thus, more patients start hemodialysis (HD) with a central venous catheter (CVC) rather than an AVF, and the supremacy of the AVF has recently been questioned. The aim of this study was to analyze the incidence and rate of access complications in 100 patients between 2010 and 2015. A total of 63 patients started HD with an AVF, while 37 began HD with a CVC. We found no differences in patient survival according to the vascular access in use at the beginning of dialysis, but patients were more likely to die while undergoing dialysis by means of a CVC than an AVF. Patients started on dialysis with a CVC had more cardiovascular disease, while patients who began dialysis with an AVF presented more hypertension. Fistulas presented a longer survival time despite more hospital admissions, but CVCs bore a higher risk of infections. Our results suggest that starting dialysis with a CVC does not confer a greater risk of death.
动静脉瘘(AVF)一直被认为是最佳的血管通路。然而,老龄透析人群不断变化的特征限制了所有患者AVF的产生。因此,更多的患者开始血液透析(HD)时使用中心静脉导管(CVC)而不是AVF,而AVF的优势最近受到质疑。本研究的目的是分析2010 - 2015年100例患者的通路并发症的发生率和发生率。共有63例患者以AVF开始HD,而37例以CVC开始HD。我们发现在透析开始时使用的血管通路在患者生存方面没有差异,但通过CVC进行透析的患者比通过AVF进行透析的患者更容易死亡。以CVC开始透析的患者有更多的心血管疾病,而以AVF开始透析的患者有更多的高血压。尽管住院次数更多,瘘管患者的生存时间更长,但cvc患者感染风险更高。我们的研究结果表明,从CVC开始透析并不会增加死亡风险。
{"title":"Vascular Access, Complications and Survival in Incident Hemodialysis Patients","authors":"M. Torreggiani, L. Bernasconi, M. Colucci, Simone Accarino, E. Pasquinucci, V. Esposito, G. Sileno, C. Esposito","doi":"10.3390/kidneydial1020013","DOIUrl":"https://doi.org/10.3390/kidneydial1020013","url":null,"abstract":"The arteriovenous fistula (AVF) has long been considered the optimal vascular access. However, the evolving characteristics of the ageing dialysis population limit the creation of an AVF in all patients. Thus, more patients start hemodialysis (HD) with a central venous catheter (CVC) rather than an AVF, and the supremacy of the AVF has recently been questioned. The aim of this study was to analyze the incidence and rate of access complications in 100 patients between 2010 and 2015. A total of 63 patients started HD with an AVF, while 37 began HD with a CVC. We found no differences in patient survival according to the vascular access in use at the beginning of dialysis, but patients were more likely to die while undergoing dialysis by means of a CVC than an AVF. Patients started on dialysis with a CVC had more cardiovascular disease, while patients who began dialysis with an AVF presented more hypertension. Fistulas presented a longer survival time despite more hospital admissions, but CVCs bore a higher risk of infections. Our results suggest that starting dialysis with a CVC does not confer a greater risk of death.","PeriodicalId":74038,"journal":{"name":"Kidney and dialysis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43280185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Dialysis Access and Preemptive Kidney Transplantation 透析途径与预防性肾移植
Pub Date : 2021-09-24 DOI: 10.3390/kidneydial1020012
Y. Mochizuki, Y. Miyata, T. Matsuda, Y. Mukae, K. Ohba, H. Sakai
Sustainable vascular or peritoneal access for dialysis is very important for patients undergoing dialysis therapy, and access trouble is occasionally involved with unexpected occurrence of complications. Once access trouble occurs, dialysis therapy might be discontinued and be followed by a life-threatening state of patients with end-stage kidney disease. Bacterial infection, massive bleeding, and thrombosis in patients undergoing hemodialysis and acute infectious peritonitis and chronic encapsulating peritoneal sclerosis in patients undergoing peritoneal dialysis are important clinical issues. Preemptive kidney transplantation prior to dialysis has several advantages over transplantation after exposure to dialysis therapy. One of the notable advantages is the lack of necessity of dialysis access, which avoids access operations before transplantation. However, some transplant recipients may need short-term dialysis therapy due to the unexpected progression of chronic renal dysfunction. Dialysis access is required in a short preoperative period for preconditioning. The selection of renal replacement therapy without complications in a short-term dialysis before transplant surgery is important for the success of kidney transplantation. Appropriate preparation of short-term dialysis therapy and access is a key to success of preemptive kidney transplantation.
持续的血管或腹膜透析通路对接受透析治疗的患者非常重要,而通道困难有时涉及意外并发症的发生。一旦出现获取困难,透析治疗可能会中断,终末期肾病患者可能会进入危及生命的状态。血液透析患者的细菌感染、大出血、血栓形成以及腹膜透析患者的急性感染性腹膜炎和慢性包裹性腹膜硬化症是重要的临床问题。在透析前进行先发制人的肾移植比透析治疗后进行移植有几个优点。其中一个显著的优点是不需要透析通道,这避免了移植前的通道手术。然而,由于慢性肾功能障碍的意外进展,一些移植受者可能需要短期透析治疗。需要在术前短时间内进行透析以进行预处理。肾移植术前短期透析选择无并发症的肾替代疗法对肾移植的成功至关重要。适当的短期透析治疗的准备和获得是先发制人肾移植成功的关键。
{"title":"Dialysis Access and Preemptive Kidney Transplantation","authors":"Y. Mochizuki, Y. Miyata, T. Matsuda, Y. Mukae, K. Ohba, H. Sakai","doi":"10.3390/kidneydial1020012","DOIUrl":"https://doi.org/10.3390/kidneydial1020012","url":null,"abstract":"Sustainable vascular or peritoneal access for dialysis is very important for patients undergoing dialysis therapy, and access trouble is occasionally involved with unexpected occurrence of complications. Once access trouble occurs, dialysis therapy might be discontinued and be followed by a life-threatening state of patients with end-stage kidney disease. Bacterial infection, massive bleeding, and thrombosis in patients undergoing hemodialysis and acute infectious peritonitis and chronic encapsulating peritoneal sclerosis in patients undergoing peritoneal dialysis are important clinical issues. Preemptive kidney transplantation prior to dialysis has several advantages over transplantation after exposure to dialysis therapy. One of the notable advantages is the lack of necessity of dialysis access, which avoids access operations before transplantation. However, some transplant recipients may need short-term dialysis therapy due to the unexpected progression of chronic renal dysfunction. Dialysis access is required in a short preoperative period for preconditioning. The selection of renal replacement therapy without complications in a short-term dialysis before transplant surgery is important for the success of kidney transplantation. Appropriate preparation of short-term dialysis therapy and access is a key to success of preemptive kidney transplantation.","PeriodicalId":74038,"journal":{"name":"Kidney and dialysis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47289403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Kidney and dialysis
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1